Clinigen Appoints James Meyer as General Manager of Commercial Medicines in the US
01 May 2019 - 11:00PM
Business Wire
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the
global pharmaceutical and services company, has appointed James
(‘Jim’) Meyer as General Manager, Commercial Medicines, US, with
immediate effect.
Jim Meyer is an accomplished and seasoned executive with nearly
40 years of experience in the pharmaceutical industry, of which
included five years at Teva Pharmaceuticals where he led the
Oncology New Products Division in the US. As the Oncology Lead, he
was responsible for the commercial development and launch of
multiple oncology products. Additionally, he played a key role in
the development of commercial strategy and business development for
the US oncology business unit. Prior to Teva, Jim spent over 27
years at Wyeth (now Pfizer) in a variety of commercial roles across
multiple therapeutic areas, including oncology.
Jim will be responsible for delivering on the Group’s strategy
in Commercial Medicines in the US. Specifically, he has been
appointed to build out Clinigen’s commercial infrastructure in the
US and to capitalise on other opportunities across the business.
This follows on from the acquisition of Proleukin® in April 2019
which created an ideal platform to expand the Group’s existing
footprint in the higher value US market where it currently owns the
US rights to Foscavir®, Ethyol® and Totect®, all of which are
distributed by third parties. Jim’s appointment demonstrates the
Group’s intent to build upon this opportunity.
Benjamin Miny, Senior Vice President of Commercial Medicines,
Clinigen Group, said:
“Jim brings in depth experience and a deep understanding of
US-based oncology sales and marketing. With this background, he is
particularly suited to building and leading the US commercial
infrastructure Clinigen needs to support its ambitions in this
market, especially following the acquisition of Proleukin. On
behalf of the team, I welcome Jim to Clinigen and look forward to
working with him.”
Jim Meyer, General Manager of Commercial Medicines, US,
Clinigen Group, said:
“Joining Clinigen at this important time in its development is a
real opportunity, and I look forward to helping with the expansion
of Clinigen’s Commercial Medicines business in the US. The
acquisition of Proleukin’s US rights gives a great platform for the
Company to grow from in North America. I believe my experience from
Teva and Wyeth will help propel Clinigen forward in this
market.”
-Ends-
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines. The Group has sites in North America,
Europe, Africa and Asia Pacific. In October 2018, the Group
acquired CSM, a specialist provider of packaging, labelling,
warehousing and distribution services, with sites in the US and
Europe, and iQone, a specialist pharmaceutical company in
Switzerland.
For more information, please visit www.clinigengroup.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190501005453/en/
Clinigen Group plcBenjamin Miny, Senior Vice President of
Commercial MedicinesMatt Parrish, Head of Investor RelationsTel:
+44 (0) 1283 495010
Instinctif PartnersMelanie Toyne-Sewell / Alex Shaw /
Deborah BellTel: +44 (0) 20 7457 2020Email:
clinigen@instinctif.com
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024